News | February 11, 2009

Personalized Medicine the Focus at 2009 Molecular Summit

February 10, 2009 – Personalized medicine will be the main topic for healthcare executives, radiologists, pathologists and information technology (IT) professionals at the second annual Molecular Summit in Philadelphia on Feb. 10-11.

Siemens Healthcare and The Dark Report bring together industry experts in molecular imaging, molecular diagnostics and IT, to discuss rapidly advancing trends in the integration of imaging and clinical laboratory diagnostics as a means to enhance predictive diagnosis and tailor effective treatment to the individual.

The Molecular Summit hopes to build on the success of last year’s program.
Conference attendees may choose from a selection of 26 educational sessions that describe how innovators are advancing clinical care and enhancing their financial strength by incorporating the latest molecular imaging techniques in tandem with emerging molecular diagnostics. Industry pioneers will speak about evolving changes in R&D, the discovery of new medicines, effective policies to translate these discoveries into better outcomes for patients, resulting treatments that improve healthcare, and new business strategies to advance the field of personalized medicine. Continuing Education Units (CEUs) are provided by the American Association of Clinical Chemistry (AACC).

More information: www.molecular-summit.com, www.usa.siemens.com/healthcare

Related Content

Combined Optical and Molecular Imaging Could Guide Breast-Conserving Surgery

WLE specimen from a patient with a grade 3, ER-/HER2-, no special type (NST) carcinoma. (A) Cerenkov image; (B) Grey-scale photographic image overlaid with Cerenkov signal. An increased signal from the tumor is visible (white arrows); mean radiance is 871 ± 131 photons/s/cm2/sr, mean TBR is 3.22. Both surgeons measured the posterior margin (outlined in blue) as 2 mm (small arrow); a cavity shaving would have been performed if the image had been available intraoperatively. The medial margin (outlined in green) measured >5 mm by both surgeons. Pathology ink prevented assessing the lateral margin; a phosphorescent signal is visible (open arrows). (C) Specimen radiography image. The absence of one surgical clip to mark the anterior margin, and the odd position of the superior margin clip (white arrow) prevented reliable margin assessment. (D) Combined histopathology image from two adjacent pathology slides on which the posterior margin (bottom of image) and part of the primary tumor are visible (open arrows). The distance from the posterior margin measured 3 mm microscopically (double arrow). The medial margin is > 5 mm (not present in image). Credit: A. D. Purushotham, M.D., King’s College London, UK

News | Nuclear Imaging | June 20, 2017
June 20, 2017 — Breast-conserving surgery (BCS) is the primary treatment for early-stage...
A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging

A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging. Graphic courtesy of the Department of Nuclear Medicine, Royal North Shore Hospital, Sydney

News | Prostate Cancer | June 15, 2017
An estimated one in seven American men will be affected by prostate cancer in their lifetime. Prostate-specific...
Axial fused 89Zr-5B1 antibody PET/CT image demonstrates focus of uptake in the liver (arrow). Focus of uptake correlates with increased liver metastasis seen on diagnostic CT (red arrow) performed 2 weeks prior

Axial fused 89Zr-5B1 antibody PET/CT image demonstrates focus of uptake in the liver (arrow). Focus of uptake correlates with increased liver metastasis seen on diagnostic CT (red arrow) performed 2 weeks prior. Image courtesy of Christian Lohrmann, Jason Lewis, Wolfgang Weber, Memorial Sloan Kettering Cancer Center; MabVax Therapeutics

News | PET-CT | June 14, 2017
Pancreatic cancer is associated with bleak five-year survival rates and limited treatment options, but new research is...

While subject No. 1 (left) was judged as positive for both the neuronal injury and the amyloid load biomarker, both Alzheimer's disease biomarkers were negative in subject No. 2 (right). Image courtesy of Henryk Barthel et al., University Hospital Leipzig, Leipzig, Germany

News | PET Imaging | June 14, 2017
More people die of Alzheimer's disease than prostate and breast cancer combined. Identifying the disease before major...
Bennett S. Greenspan, M.D.

Bennett S. Greenspan, M.D.

News | Molecular Imaging | June 13, 2017
Bennett S. Greenspan, M.D., MS, FACNM, FACR, professor of radiology at the Medical College of Georgia, Augusta...
PET/CT
News | PET-CT | June 12, 2017
Philips announced that it will be showcasing molecular imaging solutions highlighting Philips’ commitment to innovation...
News | PET-CT | June 12, 2017
Siemens Healthineers has announced that the Food and Drug Administration (FDA) has cleared Biograph Horizon Flow...
advanced visualization
News | Molecular Imaging | June 09, 2017
The Food and Drug Administration (FDA) has cleared syngo.via VB20 for Molecular Imaging (MI) from Siemens Healthineers...
Gamma Medica, LumaGEM molecular breast imaging system, MBI, Mercy Medical Center, Long Island, first New York install
News | Breast Imaging | April 04, 2017
Gamma Medica announced in late March that Mercy Medical Center, a member of Catholic Health Services of Long Island,...
Gamma Medica, European breast imaging market, LumaGem MBI, molecular breast imaging, Hospital Services Limited
News | Molecular Imaging | March 02, 2017
Gamma Medica announced it has partnered with Hospital Services Limited (HSL), a Dublin, Ireland-based established ...
Overlay Init